StockNews.AI
NVO
StockNews.AI
68 days

Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development

1. Novo Nordisk advances amycretin to phase 3 for weight management. 2. Decision based on positive regulatory feedback from phase 2 studies. 3. Phase 3 program for amycretin set to begin Q1 2026. 4. Amycretin targets adults with obesity and type 2 diabetes. 5. Novo Nordisk continues to lead in chronic disease treatments.

4m saved
Insight
Article

FAQ

Why Bullish?

Advancing amycretin to phase 3 suggests potential future revenue growth, akin to their past successes with GLP-1 therapies like Ozempic.

How important is it?

The advancement to phase 3 is a critical step for drug approval, affecting investor confidence and future revenue.

Why Long Term?

Phase 3 results could determine competitive position for a new treatment by 2026, influencing shares significantly.

Related Companies

NVOSNYLLYAMGNPFE
Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities following end-of-phase 2 interactions for subcutaneous and oral amycretin in weight management. “We are very pleased that the feedback from regulatory authorities has allowed us to take subcutaneous and oral amycretin in weight management to phase 3,” said Martin Lange, executive vice president for Development at Novo Nordisk. “We are excited about the amycretin molecule, and this marks an important step forward. We look forward to sharing more information on the design of the phase 3 programme.” Novo Nordisk is now planning to initiate a phase 3 development programme with amycretin for adults with overweight or obesity during the first quarter of 2026. About amycretinAmycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with overweight or obesity and for adults with type 2 diabetes. Amycretin is developed for subcutaneous and oral administration. Oral Amycretin Phase 1 trial - The trial evaluated the single-ascending dose and multiple-ascending doses for oral amycretin, up to 2 times 50 mg, in people with overweight or obesity, with a total treatment duration of up to 12 weeks.Subcutaneous Amycretin Phase 1b/2a trial - The trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept of once-weekly subcutaneous amycretin in people with overweight or obesity. The trial was a combined single ascending dose, multiple ascending dose and dose-response trial investigating three different maintenance doses with a total treatment duration of up to 36 weeks. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Company announcement No 17 / 2025 CA250612-amycretin-to-phase-3-clean

Related News